Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
NCT ID: NCT00258271
Last Updated: 2013-10-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
18 participants
INTERVENTIONAL
2005-03-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase I trial is studying the side effects and best dose of imatinib mesylate when given together with cladribine and cytarabine in treating patients with refractory or relapsed acute myeloid leukemia or blastic phase chronic myelogenous leukemia.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Determine the safety and feasibility of cladribine, cytarabine, and imatinib mesylate in patients with refractory or relapsed acute myeloid leukemia or blastic phase chronic myelogenous leukemia.
* Determine the maximum tolerated dose of imatinib mesylate in patients treated with this regimen.
* Correlate the expression of c-kit and the presence of c-kit mutations with clinical response in patients treated with this regimen.
* Correlate the in vitro inhibitory effects of imatinib mesylate and cytarabine on the proliferation and survival of leukemic cells with clinical response in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of imatinib mesylate.
Patients receive oral imatinib mesylate once daily on days 1-15 and cladribine IV over 2 hours and cytarabine IV over 4 hours on days 3-7. Patients also receive filgrastim (G-CSF) subcutaneously on days 2-7. Treatment repeats every 15 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of imatinib mesylate until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed periodically for up to 1 year.
PROJECTED ACCRUAL: A total of 12-18 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
filgrastim
cladribine
cytarabine
imatinib mesylate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of acute myeloid leukemia (AML) or blastic phase chronic myelogenous leukemia (CML)
* Refractory AML defined as any of the following:
* Failure to achieve complete response (CR) after 2 courses of induction chemotherapy
* Persistent bone marrow blasts \> 40% after 1 course of induction chemotherapy
* Relapse of disease within 3 months since CR
* Relapsed AML defined as the following:
* Any evidence of disease recurrence after CR (early relapse occurs within 3-12 months and late relapse occurs \> 12 months later)
* No acute promyelocytic leukemia (AML-M3 FAB subgroup)
PATIENT CHARACTERISTICS:
Performance status
* ECOG 0-2
Life expectancy
* Not specified
Hematopoietic
* Not specified
Hepatic
* Bilirubin ≤ 2.0 mg/dL
* AST ≤ 2.5 times upper limit of normal
* No known chronic liver disease (e.g., chronic active hepatitis or cirrhosis)
Renal
* Creatinine \< 2.5 mg/dL (if 2.0-2.5 mg/dL, glomerular filtration rate must be measured and dose of cytarabine adjusted if necessary)
Cardiovascular
* No New York Heart Association grade III-IV heart disease
* No congestive heart failure
* No myocardial infarction within the past 6 months
* Ejection fraction ≥ 30%
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
* No uncontrolled systemic active infection
* No known HIV infection
* No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
* No history of other curatively treated malignancy except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No other concurrent biologic agents
Chemotherapy
* See Disease Characteristics
* No other concurrent chemotherapy
Endocrine therapy
* No concurrent birth control pills
Other
* More than 1 week since any prior investigational agent
* No other concurrent investigational agents or therapies
* No other concurrent anticancer agents
* No concurrent therapeutic anticoagulation with warfarin
* Low molecular weight heparin or heparin allowed for therapeutic anticoagulation
* Mini-dose warfarin (e.g., 1 mg per day) allowed for prophylaxis of central venous catheter thrombosis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rochester
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Camille Abboud, MD
Role: PRINCIPAL_INVESTIGATOR
James P. Wilmot Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
URCC-U26403
Identifier Type: -
Identifier Source: secondary_id
URCC-RSRB-10427
Identifier Type: -
Identifier Source: secondary_id
NOVARTIS-CSTI571AUS161
Identifier Type: -
Identifier Source: secondary_id
CDR0000448638
Identifier Type: -
Identifier Source: org_study_id